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Abstract
This method provides a simple extraction procedure, as well as a validated, sensitive, and specific
liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of
ampicillin, piperacillin, tazobactam, meropenem, acyclovir, and metronidazole in human plasma.
The method was validated over concentration ranges specific for each compound, with a lower
limit of quantification of 50–300 ng/mL and a sample volume of 50 μL. The method is accurate
and precise, with within- and between-day accuracy ranging from 85–110% and 92–110%,
respectively, and within- and between-day precision of 89–111% and 91–109%, respectively.
Simplicity, low plasma volume, and high throughput make this method suitable for clinical
pharmacokinetic studies in premature infants.
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1. Introduction
Infections in premature infants (<37 weeks gestation at birth) are common and fatal [1, 2];
approximately 20% of very-low-birth-weight (<1500 g) infants suffer from culture-proven
sepsis, and 10–20% die [1, 2]. To prevent these devastating consequences, more than 90%
of infants born <33 weeks gestational age and admitted to the nursery are treated with
multiple antimicrobial agents [3]. In spite of the widespread use of antimicrobials in this
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population, pharmacokinetic (PK) studies in premature infants are exceptionally scarce. This
is due, in part, to limitations inherent to trials involving premature infants, including limited
blood volume necessary to conduct PK studies and lack of availability of sensitive and
specific drug concentration assays.
Over the last two decades, advances in technology have provided tools to measure drug
concentration in biological matrices accurately, selectively, and with increased sensitivity.
Optimized methods using high-performance liquid chromatography (HPLC) and the
incorporation of mass spectrometry (MS) have resulted in the ability to measure drug
concentrations in low (<100 uL) plasma volume. In addition, given the ability of these
instruments to separate compounds efficiently, it is now possible to measure several
compounds in the same sample simultaneously [4]. This methodology has been successful in
several settings, including measurement of antiretroviral drugs from different drug classes
[5] and simultaneous measurements of antimicrobials [6, 7]. In premature infants, the
multiplex-assay approach is attractive because these patients are often treated with several
antimicrobials concomitantly. More importantly, in the setting of clinical trials where each
infant receives a different antimicrobial agent, a single multiplex assay increases trial
efficiency by measuring drug concentrations of all agents without the need to develop and
validate multiple individual assays specific for each drug. Therefore, the purpose of this
work was to develop and validate a LC-MS/MS multiplex drug concentration assay for
commonly used antimicrobials in premature infants, including ampicillin, piperacillin,
tazobactam, meropenem, acyclovir, and metronidazole.
2. Experimental
2.1. Chemicals and reagents
Ampicillin, piperacillin, acyclovir, metronidazole, and dicloxacillin (internal standard [IS])
were purchased from the Sigma Chemical Company (St. Louis, MO, USA). Tazobactam and
meropenem were purchased from the U.S. Pharmacopeia (Rockville, MD, USA). HPLC-
grade chemicals were purchased from Fisher Scientific (Norcross, GA, USA). Purified
compressed nitrogen was obtained from Airgas-National Welders (Charlotte, NC, USA).
Drug-free pooled plasma was obtained from Biological Specialty Corporation (Colmar, PA,
USA). Plasma obtained from whole blood anticoagulated with potassium tri-phosphate
EDTA was obtained from Biological Specialty Corporation.
2.2. Equipment
Compounds were analyzed with a triple quadrupole mass spectrometer API 4000 (Applied
Biosystems–ABSciex, Foster City, CA, USA). A Shimadzu solvent delivery system
(Columbia, MD, USA), LEAP HTC PAL thermostatted autosampler (Carrboro, NC, USA),
Valco switching valve (Houston, TX, USA), and Analyst Software version 1.4.1 (Applied
Biosystems–ABSciex, Foster City, CA, USA) run on a Dell desktop computer (operated by
Windows XP professional) were used for this method.
2.3. Preparation of standards
Individual clear stock solutions of ampicillin, piperacillin, tazobactam, meropenem,
acyclovir, and metronidazole were prepared at the following concentrations: ampicillin,
piperacillin, and tazobactam 15 mg/mL, meropenem and acyclovir 5 mg/mL, and
metronidazole 2.5 mg/mL. Each analyte was accurately weighed and dissolved in dimethyl
sulfoxide (DMSO) according to Table 1.
The master stock solution was prepared as a composite of all six compounds (0.5 mL each),
adjusted to a final concentration of 1,500,000 ng/mL for ampicillin, piperacillin, and
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tazobactam; 500,000 ng/mL for meropenem and acyclovir; and 250,000 ng/mL for
metronidazole, by 2.0 mL of DMSO. This master stock standard was used to prepare seven
intermediate composite stock solutions: ampicillin and piperacillin (1,500,000; 750,000;
300,000; 150,000; 30,000; 15,000; and 3,000 ng/mL); tazobactam (750,000; 300,000;
150,000; 30,000; 15,000; 3,000; and 1,500 ng/mL); meropenem and acyclovir (500,000;
250,000; 100,000; 50,000; 10,000; 5,000; and 1,000 ng/mL); and metronidazole (250,000;
125,000; 50,000; 25,000; 5,000; 2,500; and 500 ng/mL) in DMSO.
Plasma working calibration solutions at 150,000, 75,000, 30,000, 15,000, 3,000, 1,500, and
300 ng/mL for ampicillin and piperacillin; 75,000, 30,000, 15,000, 3,000, 1,500, 300, and
150 ng/mL for tazobactam; 50,000, 25,000, 10,000, 5,000, 1,000, 500, and 100 ng/mL for
meropenem and acyclovir; and 25,000, 12,500, 5,000, 2,500, 500, 250, and 50 ng/mL for
metronidazole were prepared by diluting the intermediate solutions in human drug-free
plasma in a ratio of 1:9.
From the master and intermediate stock solutions, quality control (QC) intermediate stock
solutions were prepared in DMSO at concentrations of 9,000, 600,000, and 1,200,000 ng/
mL ampicillin and piperacillin; 4,500, 180,000, and 600,000 ng/mL for tazobactam; 3,000,
200,000, and 400,000 ng/mL for meropenem and acyclovir; and 1,500, 100,000, and
200,000 ng/mL for metronidazole. Plasma working QC samples of 900, 60,000, and 120,000
ng/mL for ampicillin and piperacillin; 450, 18,000, and 60,000 ng/mL for tazobactam; 300,
20,000, and 40,000 ng/mL for meropenem and acyclovir; and 150, 10,000, and 20,000 ng/
mL for metronidazole were prepared by diluting the QC intermediate solutions in human
drug-free plasma in a ratio of 1:9.
2.4. Internal standard preparation
Dicloxacillin (1 mg) was weighed and dissolved in DMSO to achieve a final concentration
of 1.0 mg/mL (stock solution). The internal standard working solution was prepared by
diluting 0.3 mL of this solution in 99.7 mL of acetonitrile to achieve a final concentration of
3,000 ng/mL.
2.5. Samples and pre-treatment
This method was used to measure antimicrobial concentrations in clinical samples collected
from premature infants at pre-specified time points or scavenged from the clinical laboratory
after processing for clinical care. Sample collection (∼200–1000 μL, heparinized or
ethylenediaminetetraacetic acid [EDTA] tubes) occurred under an investigational protocol
approved by the institutional review board at participating sites and after informed consent
was obtained from caregivers of study participants. Blood samples at pre-specified time
points were collected and kept on ice after collection for a maximum of 15 minutes. Blood
plasma was separated by centrifugation for 10 minutes. Plasma samples were transferred to
a −80° C temperature-monitored freezer for storage until analysis. Prior to extraction, all
plasma samples were brought to room temperature and then gently mixed.
2.6. The extraction procedure
On the day of analysis, 200 μL of chilled (left in the refrigerator for 20 minutes) internal
standard was placed into a 2.0 mL labeled conical plastic Eppendorf tube, followed by 45
μL of plasma and 5 μL of DMSO (for blank and patient samples) or by 50 μL of spiked
plasma (for calibrators and QC samples). The DMSO was added to the blank and patient
samples to compensate for the DMSO added to the plasma working calibration solutions.
The solutions were vortex-mixed for 15 minutes and centrifuged at 15,600 g at 4° C for 10
minutes. The supernatant portion was transferred into a 96-insert holder with 0.7 mL glass
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inserts (Q Glass, NJ, USA). The inserts on the holder were tightly sealed with a silicone 96-
insert cover.
2.7. LC-MS/MS analysis
Ampicillin, piperacillin, acyclovir, meropenem, and metronidazole were analyzed in positive
mode. Tazobactam was analyzed in negative mode during a separate injection run from the
same glass insert. Dicloxicillin was used as internal standard for both positive and negative
analyses. The injection volume was 4 μL.
Chromatography was achieved by using a reverse-phase C18 Aquasil column (50 × 2.1-mm
internal diameter, 5 μm particle size; Thermo Fisher, Waltham, MA, USA) with a flow rate
of 0.75 ml/min for analysis in positive mode and a C18 Ultra Aqueous column (50 × 2.1-
mm internal diameter, 3 μm particle size; Restek, Bellefonte, PA, USA) with a flow rate of
0.35 ml/min for analysis in negative mode. In both analyses, mobile phase A consisted of
0.1% formic acid in water, and mobile phase B consisted of 0.1% formic acid in methanol.
The chromatographic separation of analytes was performed with gradient elution of
increasing mobile phase B (0% hold until 0.7 minutes, 0–15% from 0.7–1 minute, 15–100%
from 1–4 minutes, 100% hold from 4–4.5 minutes, 0% from 4.5–6 minutes for positive
mode; 0% hold until 0.7 minutes, 0–100% from 0.7–2.5 minutes, 100% hold from 2.5–3.5
minutes, 0% from 3.5–5 minutes for negative mode). Flow was diverted to waste for the first
0.7 minutes and after 4 minutes. Total run time was 6 and 5 minutes for positive and
negative mode, respectively.
MS/MS analysis was performed on a triple quadrupole mass spectrometer API 4000
(Applied Biosystems–ABSciex, Foster City, CA, USA) operated with electrospray
ionization (TurboV source using the electrospray probe). Ionspray voltage and turbo heater
temperature were kept at 2500 V (-2000 V for tazobactam) and 500° C, respectively.
Compound-specific instrument parameters were optimized for each transition (Table 2) to
obtain the most robust signal.
2.8. Linearity, limit of quantification, and limit of detection
Linearity was assessed using five calibration curves analyzed on separate days. For
validation, each point on the calibration curve was run in duplicate (two separate
extractions), and the curves were constructed by calculating the peak area ratios of each
compound to the internal standard and plotting these against the nominal concentration of
the sample. Back-calculated calibration concentrations were determined using several
models. The calibration curve with the best accuracy and precision throughout the curve
range was considered the best fit. Quadratic regression of the ratio of compound to internal
standard concentration (x) versus peak area ratio of compound to internal standard (y) using
a 1/(x) weighting scheme was used for calculations because it provided the best fit to the
data.
The upper limit of quantification (ULOQ) was defined as the highest standard concentration
for which both the relative standard deviation and the percent deviation from the nominal
concentration were less than 15% [8]. The lower limit of quantification (LLOQ) was defined
as the lowest concentration for which both the relative standard deviation and the percent
deviation from the nominal concentration were less than 20%. The detection limit was
defined as signal to noise ratio of 3:1.
2.9. Matrix effects
Seven different lots from two separate plasma matrices (two lots sodium heparin and five
lots potassium tri-phosphate EDTA) were spiked in triplicate, extracted, and analyzed as
Cohen-Wolkowiez et al. Page 4













separate samples. The following compound concentrations were tested: 18,000 ng/mL for
ampicillin, piperacillin, and tazobactam; 6,000 ng/mL for meropenem and acyclovir; and
3,000 ng/mL for metronidazole. Calculated concentrations for each extracted lot were
compared to theoretical concentrations. In addition, the method's specificity was tested by
screening the seven different human blank plasma lots for drugs and internal standard.
2.10. Accuracy, precision, and recovery (extraction efficiency)
Accuracy and precision of the analytical method was quantified using four concentrations of
QC samples (including LLOQ) run six times (six separate extractions) in sequence on five
different days (total of 30 replicates for each concentration). In addition, accuracy and
precision of diluted samples were determined. Dilutions (1:1, 1:3, and 1:9 ratios) of a highly
concentrated solution (300,000 ng/mL for ampicillin, piperacillin, and tazobactam; 100,000
ng/mL for meropenem and acyclovir; and 50,000 ng/mL for metronidazole) were performed
with human plasma. The calculated concentrations were compared to the nominal
concentrations.
Recovery (extraction efficiency) of the six compounds was determined with QC samples (all
three QC concentration levels) by dividing the peak area of the extracted spiked plasma
samples with the peak area of a spiked blank plasma extract.
2.11. Stability
To test stability, samples were left at room temperature for 24 hours prior to extraction.
Stability during sample handling was also verified by subjecting samples to either three
freeze-thaw cycles or storage for 24 hours in the refrigerator at 4° C prior to extraction. QC
samples at the three concentrations were used for this purpose. Also, stability in the
autosampler for 24 hours was tested. One-month stability was tested by storing aliquots of
QC samples for one month in the -80° C freezer.
3. Results
3.1. Linearity
The calibration curve was calculated using peak area ratio values at seven standard
concentrations. A quadratic regression provided the best fit to the data. The data for the
calibration curves (n=5) are shown in Table 3, along with the mean ± standard deviation of
five standard curve quadratic coefficients, slopes, intercepts, and correlation coefficients
(r2). The regression coefficient (r2) for all calibration curves was greater than 0.9965. Due to
day-to-day variations in the coefficients of the quadratic equation, standards and QCs should
be generated for each day of analysis.
3.2. Matrix effect
The percent difference from theoretical concentrations for all analytes was less than 15%,
except for acyclovir (21% difference, lot #1) and meropenem (26% difference, lot #3)
(Table 4). Therefore, the extraction method was suitable for all analytes spiked in these
matrices, except for the lots mentioned above. In addition, no response in MS/MS channels
used for monitoring both drugs and internal standards was observed in any of the seven
human plasma lots.
3.3. The limit of quantification
The LLOQ for ampicillin, piperacillin, tazobactam, metronidazole, meropenem, and
acyclovir were 300, 300, 150, 50, 100, and 100 ng/mL, respectively, and the ULOQ for
ampicillin, piperacillin, tazobactam, metronidazole, meropenem, and acyclovir were
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150,000, 150,000, 75,000, 25,000, 50,000, and 50,000 ng/mL, respectively. Chromatograms
of blank, LLOQ, and ULOQ samples are shown in Fig. 1 and Fig. 2
3.4. Accuracy, precision, and recovery
The results of the accuracy and precision experiments at four different quality control levels
are shown in Table 5. Within-day accuracy of all analytes ranged from 85–110%, with a
mean of 101%. Between-day accuracy of all analytes ranged from 92–110%, with a mean of
101%. Within- and between-day coefficient of variations varied from 2.1–11.4%, and 4.0–
9.1%, respectively. Overall, results indicate that the method was accurate and precise for
each compound. In addition, concentration measurements of partially diluted samples were
accurate and precise across all dilution ratios. The greatest percent deviation for all diluted
samples was 16.8% for metronidazole when diluted 1:9. The greatest % coefficient of
variation for all the diluted samples was 14.1%. The absolute recovery of all compounds at
all concentrations was greater than 75% (Table 3).
3.5. Stability
Overall, each compound was stable under most tested conditions, with a few exceptions.
After 24 hours at room temperature, all compound concentrations were within 15% of
nominal, with the exception of tazobactam (82% of nominal), piperacillin (75%), and
meropenem (84%). In three freeze-thaw cycles, on average all compound concentrations
were within 10% of nominal. The low QC for ampicillin deviated 16% from nominal. All
compounds were stable when left in the autosampler for 24 hours at 8° C (within 12% of
nominal concentration)and all compounds were stable when left in the refrigerator (4° C) for
24 hours, being within 13% of the nominal concentration. In addition, after one month of
storage at <70° C, all compounds were within 15% of controls.
3.6. Analysis of patient samples
We evaluated the applicability of the described method by analyzing sparse plasma samples
collected from premature infants (<32 weeks gestational age at birth, N=8) given multiple
intravenous doses of piperacillin-tazobactam (Table 6). Piperacillin and tazobactam were
found in almost all patient samples. The mean (SD) estimated gestational age at birth,
postnatal age, and birth weight was 25 (2.7) weeks, 7 (7) days, 728 (185) grams,
respectively. The overall mean (SD) piperacillin concentration was 41,123 (53,789) ng/mL;
the mean (SD) piperacillin concentration in infants < and ≥ 28 weeks postmenstrual age
were 45,159 (58,686, n=6) and 24,310 (20,186, n=2) ng/mL, respectively. In addition to
piperacillin and tazobactam, ampicillin was found in five patients, metronidazole in three
patients, and acyclovir in one patient. Meropenem was not found in any of the samples.
Dosing of these agents could be confirmed in 7/8 patients.
4. Discussion
The method described in this report measures drug concentration of six antimicrobials
accurately and precisely in micro-volumes (50 μL) of plasma. Previous investigators have
developed analytical methods to measure drug concentrations of antimicrobials in low
plasma volumes; however, most involve antimicrobials of the same drug class and no
antivirals [4]. The ability to simultaneously measure drug concentrations of antimicrobials
from different classes, including antivirals, is an important milestone in evaluating drug
disposition in premature infants. The latter is often challenging due to blood volume
limitations in this population; therefore, drug concentration information obtained from each
sample should be maximized. This can be accomplished with this assay as premature infants
are often treated with several antimicrobials simultaneously. The latter is evidenced in the
patient samples tested, as acyclovir and metronidazole were found in some of the infants
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treated with piperacillin-tazobactam. A high degree of variability and a trend towards
decreasing piperacillin concentrations was observed with increasing postmenstrual age.
Even though it is not possible to perform formal statistical inferences to assess significance
of piperacillin concentration differences between postmenstrual age groups, it is likely that
these differences result from maturational changes characteristic of the developing infant.
These developmental changes are often related to improvement in renal function that leads
to increased piperacillin clearance. This observation has been demonstrated in previous
studies evaluating the PK of piperacillin in more mature premature infants [9]. A formal
population PK analysis is underway to quantify and identify sources of variability in
piperacillin concentrations in this population.
In addition to the advantages offered by micro-volumes and multiplex methodologies in
premature infant studies, dried blood spot (DBS) sampling is becoming an attractive
technology for use in this population. This technology requires minimum amounts of whole
blood per sample (<30 μL), virtually no sample processing, and convenient room
temperature storage. Even though several bioanalytical assays have been developed using
DBS technology, only one clinical study has evaluated the use of DBS in premature infants
[10]. The utility of this technology across therapeutics in this population remains to be
determined.
The extraction process (protein precipitation) used for this method has been previously
described for beta-lactam antibiotics [4]. In the present method, this simple and
straightforward extraction process provided excellent recovery (>90%) for most compounds.
It is possible that the compounds with the lowest extraction efficiency (77–83%),
meropenem and acyclovir, remained trapped in the protein precipitate or did not completely
dissolve into the organic phase. In spite of this limitation, the extraction procedure used in
this method provides a high level of efficiency in sample preparation, as well as high
throughput processing of patient samples.
Although clinical plasma samples >50 μL from premature infants can be obtained, it is not
without difficulty. This assay was designed to use sample volumes as low as 5 μL, which
holds a number of advantages. Samples requiring repeat analysis can be diluted (1:1, 1:3, or
1:9) with blank plasma and extracted. This is particularly advantageous for concentrations
>ULOQ that need to be diluted back into the curve. Samples known to contain beta-lactams
(tazobactam, piperacillin, meropenem) should be handled carefully given the lack of
stability of these compounds at room temperature. Freeze-thaw cycles, however, did not
affect the stability of any of the compounds, which allows for retesting of samples if needed.
5. Conclusion
We successfully developed a method to simultaneously assay ampicillin, piperacillin,
tazobactam, meropenem, acyclovir, and metronidazole in human plasma. The assay has been
validated with respect to accuracy, precision, limit of detection, recovery, and stability
(except as noted). The assay has been successfully applied to clinical samples from
premature infants. This method has many clinical applications within the field of pediatrics,
as it is simple, highly sensitive and specific, and requires an micro-volumes of sample.
Acknowledgments
The authors received funding from the following: Michael Cohen-Wolkowiez receives support from NICHD
1K23HD064814-01, and from the non-profit organization Thrasher Research Foundation.
Nicole R. White receives support from the U.S. government for work in clinical pharmacology (P30AI37260).
Cohen-Wolkowiez et al. Page 7













Arlene Bridges receives support from the U.S. government for her work in developing analytical methods for novel
nanoparticle based therapies (1-54-CA151652-01, Carolina Center of Cancer Nanotechnology Excellence,
DeSimone, PI).
Daniel K. Benjamin Jr. receives support from the U.S. government for his work in pediatric and neonatal clinical
pharmacology (1R01HD057956-02, 1R01FD003519-01, 1U10-HD45962-06, 1K24HD058735-01, and
Government Contract HHSN267200700051C), the nonprofit organization Thrasher Research Foundation for his
work in neonatal candidiasis, and from industry for neonatal and pediatric drug development
(http://www.dcri.duke.edu/research/coi.jsp).
Angela D. M. Kashuba receives support from the U.S. government for work in clinical pharmacology
(R34AI087065, P30AI37260), from industry for clinical pharmacology (Pfizer, Gilead, Abbott, Tibotec, and
Merck), and from the North Carolina Translational and Clinical Sciences Institute.
References
1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan
EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK,
Papile LA, Poole WK. Pediatrics. 2002; 110:285–291. [PubMed: 12165580]
2. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, Laptook A, Walsh M, Oh W,
Hale E. Pediatr Infect Dis J. 2005; 24:635–639. [PubMed: 15999007]
3. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Pediatrics. 2006; 117:1979–1987. [PubMed:
16740839]
4. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Antimicrob Agents Chemother. 2009; 53:75–
80. [PubMed: 18955527]
5. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD. Biomed Chromatogr. 2007; 21:1095–
1104. [PubMed: 17582235]
6. Denooz R, Charlier C, Chromatogr J, Analyt B. Technol Biomed Life Sci. 2008; 864:161–167.
7. Holt DE, de Louvois J, Hurley R, Harvey D, Antimicrob J. Chemother. 1990; 26:107–115.
8. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik
RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Pharm Res. 2000; 17:1551–1557.
[PubMed: 11303967]
9. Kacet N, Roussel-Delvallez M, Gremillet C, Dubos JP, Storme L, Lequien P. Pediatr Infect Dis J.
1992; 11:365–369. [PubMed: 1630856]
10. Suyagh M, Collier PS, Millership JS, Iheagwaram G, Millar M, Halliday HL, McElnay JC.
Pediatrics. 2011; 127:e367–e374. [PubMed: 21220396]
Cohen-Wolkowiez et al. Page 8














• We describe a method that provides a simple extraction procedure, as well as a
validated, sensitive, and specific liquid chromatography-tandem mass
spectrometry assay for the simultaneous quantification of ampicillin,
piperacillin, tazobactam, meropenem, acyclovir, and metronidazole in human
plasma.
• The ability to simultaneously measure drug concentrations of antimicrobials
from different classes, including antivirals, is an important milestone in
evaluating drug disposition in premature infants. The latter is often challenging
due to blood volume limitations in this population, therefore, drug concentration
information obtained from each sample should be maximized.
• This can be accomplished with this assay as premature infants are often treated
with several antimicrobials simultaneously.
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Blank plasma sample run in a) negative (tazobactam) and b) positive (top to bottom:
metronidazole, acyclovir, ampicillin, meropenem, piperacillin) ionization mode.
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Lower limit of quantification in a) negative (top to bottom: tazobactam and dicloxacillin
[IS]) and b) positive (top to bottom: dicloxacillin [IS], metronidazole, acyclovir, ampicillin,
meropenem, piperacillin) ionization mode. Upper limit of quantification in c) negative (top
to bottom: tazobactam and dicloxacillin [IS]) and d) positive (top to bottom: dicloxacillin
[IS], metronidazole, acyclovir, ampicillin, meropenem, piperacillin) ionization mode.
IS=internal standard.
Cohen-Wolkowiez et al. Page 15







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2012 November 15.
